Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Nephrology

Pathology & Understanding Your Kidney Biopsy Report

At a Glance

A kidney biopsy report for MPGN or C3G uses light microscopy, immunofluorescence, and electron microscopy to diagnose the disease. Key findings include tram-tracking of the kidney filters, the presence of specific immune proteins like C3, and the exact location of deposits.

A kidney biopsy report is a technical document, but it is also the “map” of your disease. To understand it, you need to look at three different “camera lenses” the pathologist uses to examine your kidney tissue. Each lens reveals a different layer of information about the damage and its cause [1][2].

1. Light Microscopy: The “Big Picture”

This is the first lens. It shows the general structure of the kidney’s filters (glomeruli). In an MPGN pattern, the pathologist looks for two classic signs:

  • Tram-Tracking: Also called double contours, this occurs when the filter wall (the basement membrane) splits or duplicates [3][4]. It looks like a set of railroad tracks under the microscope.
  • Hypercellularity: This means there are too many cells in the mesangium (the scaffolding of the filter), making the filter look crowded and “lobular” [5][4].

2. Immunofluorescence (IF): Identifying the “Driver”

The second lens uses fluorescent stains to see which immune system proteins are stuck in the kidney. This is how doctors distinguish between IC-MPGN and C3G [6][7]:

  • IC-MPGN: The report will show both immunoglobulins (like IgG, IgA, or IgM) and complement (C3) [6][8].
  • C3G (C3 Glomerulopathy): This is defined by “C3-dominance.” For this diagnosis, the C3 staining must be significantly stronger—usually at least two levels higher—than any other immune marker [9].

3. Electron Microscopy (EM): The “Deep Dive”

The third lens is the most powerful. It allows the pathologist to see exactly where the deposits are located. This lens is used to split C3G into two subtypes [10][11]:

  • Dense Deposit Disease (DDD): The pathologist sees extremely dark, “ribbon-like” or “sausage-shaped” deposits living inside the filter wall [12][13].
  • C3 Glomerulonephritis (C3GN): The deposits are more scattered and found in various places, like the mesangium or the subendothelial space, but they lack the distinct ribbon look of DDD [14][12].

Uncovering “Masked” Deposits

In some cases, a biopsy might look like C3G (only C3 is visible), but the patient actually has MGRS (a monoclonal protein disease). This happens because the abnormal proteins can be “masked” or hidden by the way the tissue was prepared [1][15].

If your initial report shows only C3 but your doctor suspects an underlying protein issue, they may order specialized tests like paraffin-IF or pronase digestion [1][16]. These techniques “unmask” hidden proteins, ensuring you aren’t misdiagnosed [1][17].

Biopsy Completeness Checklist

A complete MPGN or C3G biopsy report should ideally include all of the following:

  • Light Microscopy: Mentions of “tram-tracking,” “double contours,” or “mesangial hypercellularity.”
  • Stains: Confirmation that silver (Jones) or PAS stains were used to see the filter walls [1].
  • Immunofluorescence (IF): Specific intensity scores (0 to 3+) for IgG, IgA, IgM, C3, C1q, Kappa, and Lambda.
  • Electron Microscopy (EM): Description of where the “electron-dense deposits” are located (intramembranous vs. subendothelial).
  • MGRS Check: If C3 is dominant, a note on whether “masked” deposits were ruled out, especially in patients over age 50 [17].

Return to Home

Common questions in this guide

What does 'tram-tracking' or 'double contours' mean on my kidney biopsy?
Tram-tracking occurs when the kidney's filter wall splits or duplicates, looking like a set of railroad tracks under a microscope. It is a classic sign of an MPGN pattern of kidney damage.
How does a biopsy show the difference between IC-MPGN and C3G?
Pathologists use immunofluorescence to identify specific immune system proteins. If both immunoglobulins and complement (C3) are present, it is typically IC-MPGN. C3G is diagnosed when C3 staining is significantly stronger than other markers.
What is the difference between Dense Deposit Disease (DDD) and C3GN?
Both are types of C3 Glomerulopathy, but they look different under an electron microscope. DDD has extremely dark, ribbon-like deposits inside the filter wall, while C3GN deposits are more scattered and lack the ribbon appearance.
What are 'masked' deposits in a kidney biopsy?
Sometimes abnormal proteins are hidden by the way biopsy tissue is prepared, making a disease look like C3G. Doctors can use special tests like pronase digestion to unmask these hidden proteins and ensure an accurate diagnosis.
What information should be included in a complete kidney biopsy report?
A complete report should include results from light microscopy, immunofluorescence (with specific intensity scores for markers like IgG and C3), and electron microscopy to detail the exact location of deposits.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my report mention 'tram-tracking' or 'double contours' on light microscopy?
  2. 2.On my immunofluorescence results, what were the exact intensities of C3 versus IgG, IgA, and IgM?
  3. 3.Did electron microscopy show the 'ribbon-like' deposits characteristic of Dense Deposit Disease (DDD)?
  4. 4.Was 'pronase digestion' or 'paraffin-IF' performed to ensure no 'masked' monoclonal proteins were missed?
  5. 5.Are there any signs of chronic damage, like fibrosis, mentioned in the report?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits.

    Larsen CP, Messias NC, Walker PD, et al.

    Kidney international 2015; (88(4)):867-73 doi:10.1038/ki.2015.195.

    PMID: 26154922
  2. 2

    Repeated Kidney Biopsy in Membranoproliferative Glomerulonephritis.

    Li AH, Li Y, Li MS, et al.

    Kidney diseases (Basel, Switzerland) 2025; (11(1)):258-269 doi:10.1159/000545727.

    PMID: 40337160
  3. 3

    Characteristics and outcomes of glomerulonephritis with membranoproliferative pattern in children.

    Xu L, Wei F, Feng J, et al.

    Translational pediatrics 2021; (10(11)):2985-2996 doi:10.21037/tp-21-286.

    PMID: 34976764
  4. 4

    Clinical and histological features of patients with membranoproliferative glomerulonephritis classified by immunofluorescence findings.

    Dias CB, Testagrossa L, Jorge L, et al.

    Jornal brasileiro de nefrologia 2017; (39(4)):447-453 doi:10.5935/0101-2800.20170078.

    PMID: 29319772
  5. 5

    Mesangiocapillary glomerulonephritis complicating pulmonary tuberculosis.

    Torpiano P, Holwill S, Pace D

    CEN case reports 2022; (11(1)):17-21 doi:10.1007/s13730-021-00626-6.

    PMID: 34260011
  6. 6

    C3G and Ig-MPGN-treatment standard.

    Noris M, Remuzzi G

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2024; (39(2)):202-214 doi:10.1093/ndt/gfad182.

    PMID: 37604793
  7. 7

    [Diagnosis and treatment of glomerular diseases with a membranoproliferative glomerulonephritis (MPGN) pattern of injury].

    Rudnicki M, Windpessl M, Eller K, et al.

    Wiener klinische Wochenschrift 2023; (135(Suppl 5)):688-695 doi:10.1007/s00508-023-02264-7.

    PMID: 37728653
  8. 8

    Pegcetacoplan-induced remission in pediatric immune-complex membranoproliferative glomerulonephritis with comorbid autosomal recessive polycystic kidney disease: a case report.

    Alrasheed R, Alanazi A, Bukhari R, et al.

    Frontiers in medicine 2026; (13()):1668375 doi:10.3389/fmed.2026.1668375.

    PMID: 41884136
  9. 9

    Clinico-Pathogenic Similarities and Differences between Infection-Related Glomerulonephritis and C3 Glomerulopathy.

    Wada Y, Kamata M, Miyasaka R, et al.

    International journal of molecular sciences 2023; (24(9)) doi:10.3390/ijms24098432.

    PMID: 37176142
  10. 10

    Primary membranoproliferative glomerulonephritis: natural history, pathogenesis, and treatment.

    Filippone EJ, Farber JL

    Frontiers in nephrology 2026; (6()):1747678 doi:10.3389/fneph.2026.1747678.

    PMID: 41767602
  11. 11

    Electron Microscopy in Renal Biopsy Interpretation: When and Why It Still Matters.

    Qasim H, Hayajneh Z, Khattab K, et al.

    Cureus 2025; (17(11)):e96311 doi:10.7759/cureus.96311.

    PMID: 41367485
  12. 12

    Diagnosis of complement alternative pathway disorders.

    Angioi A, Fervenza FC, Sethi S, et al.

    Kidney international 2016; (89(2)):278-88.

    PMID: 26806831
  13. 13

    Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy.

    Madden B, Singh RD, Haas M, et al.

    Kidney international 2024; (105(5)):1077-1087 doi:10.1016/j.kint.2024.02.013.

    PMID: 38447879
  14. 14

    Infection-related Glomerulonephritis and C3 Glomerulonephritis - Similar Yet Dissimilar: A Case Report and Brief Review of Current Literature.

    Chamarthi G, Clapp WL, Bejjanki H, et al.

    Cureus 2020; (12(2)):e7127 doi:10.7759/cureus.7127.

    PMID: 32140372
  15. 15

    Utility of immunohistochemistry with C3d in C3 glomerulopathy.

    Snijders MLH, van de Wall-Neecke BJ, Hesselink DA, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020; (33(3)):431-439 doi:10.1038/s41379-019-0348-z.

    PMID: 31477814
  16. 16

    Direct immunofluorescence on formalin-fixed, paraffin-embedded versus fresh frozen human renal biopsies: a comparative study.

    Eidan AJ

    Journal of immunoassay & immunochemistry 2024; (45(3)):292-305 doi:10.1080/15321819.2024.2306324.

    PMID: 38263688
  17. 17

    C3 glomerulonephritis associated with monoclonal gammopathy of renal significance: case report.

    Alonso-Titos J, Perea-Ortega L, Sola E, et al.

    BMC nephrology 2018; (19(1)):129 doi:10.1186/s12882-018-0927-0.

    PMID: 29884135

This page explains kidney biopsy pathology terminology for educational purposes. Your nephrologist and pathologist are the best sources for interpreting your specific biopsy report.

Get notified when new evidence is published on Primary membranoproliferative glomerulonephritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.